Nuclear Medicine and Biology
Volume 35, Issue 6 , Pages 673-678 , August 2008

Enhancement of somatostatin-receptor-targeted 177Lu-[DOTA0-Tyr3]-octreotide therapy by gemcitabine pretreatment-mediated receptor uptake, up-regulation and cell cycle modulation

  • Tapan K. Nayak

      Affiliations

    • College of Pharmacy, University of New Mexico, Albuquerque, NM 87131, USA
    • Department of Cell Biology and Physiology, School of Medicine, University of New Mexico, Albuquerque, NM 87131, USA
    • Current address: Radiation Oncology Branch, National Cancer Institute, National Institute of Health, Bethesda, MD 20892, USA.
    • ,
  • Robert W. Atcher

      Affiliations

    • College of Pharmacy, University of New Mexico, Albuquerque, NM 87131, USA
    • Bioscience Division, Los Alamos National Laboratory, Los Alamos, NM 87545, USA
    • ,
  • Eric R. Prossnitz

      Affiliations

    • Department of Cell Biology and Physiology, School of Medicine, University of New Mexico, Albuquerque, NM 87131, USA
    • Cancer Research and Treatment Center, University of New Mexico, Albuquerque, NM 87131, USA
    • ,
  • Jeffrey P. Norenberg

      Affiliations

    • College of Pharmacy, University of New Mexico, Albuquerque, NM 87131, USA
    • Cancer Research and Treatment Center, University of New Mexico, Albuquerque, NM 87131, USA
    • Corresponding Author InformationCorresponding author. College of Pharmacy, University of New Mexico, Albuquerque, NM 87131 0001, USA.

Received 27 February 2008 ,Revised 30 April 2008 ,Accepted 9 May 2008.

References 

  1. Van Essen M, Krenning EP, De Jong M, Valkema R, Kwekkeboom DJ. Peptide Receptor Radionuclide Therapy with radiolabelled somatostatin analogues in patients with somatostatin receptor positive tumours. Acta Oncol. 2007;46(6):723–734
  2. Krenning EP, Kwekkeboom DJ, Valkema R, Pauwels S, Kvols LK, De Jong M. Peptide receptor radionuclide therapy. Ann N Y Acad Sci. 2004;1014:234–245
  3. Kwekkeboom DJ, Teunissen JJ, Bakker WH, Kooij PP, et al. Radiolabeled somatostatin analog [177Lu-DOTA0,Tyr3]octreotate in patients with endocrine gastroenteropancreatic tumors. J Clin Oncology. 2005;23(12):2754–2762
  4. Otte A, Herrmann R, Heppeler A, Behe M, Jermann E, Powell P, et al. Yttrium-90 DOTATOC: first clinical results. Eur J Nucl Med. 1999;26(11):1439–1447
  5. Nayak TK, Norenberg JP, Anderson TL, Prossnitz ER, Stabin MG, Atcher RW. Somatostatin-receptor-targeted alpha-emitting (213)Bi is therapeutically more effective than beta(−)-emitting (177)Lu in human pancreatic adenocarcinoma cells. Nucl Med Biol. 2007;34(2):185–193
  6. Nayak T, Norenberg J, Anderson T, Atcher R. A comparison of high- versus low-linear energy transfer somatostatin receptor targeted radionuclide therapy in vitro. Cancer Biother Radiopharm. 2005;20(1):52–57
  7. Norenberg JP, Krenning BJ, Konings IR, Kusewitt DF, Nayak TK, Anderson TL, et al. 213Bi-[DOTA0, Tyr3]octreotide peptide receptor radionuclide therapy of pancreatic tumors in a preclinical animal model. Clin Cancer Res. 2006;12(3 Pt 1):897–903
  8. Fueger BJ, Hamilton G, Raderer M, Pangerl T, Traub T, Angelberger P, et al. Effects of chemotherapeutic agents on expression of somatostatin receptors in pancreatic tumor cells. J Nucl Med. 2001;42(12):1856–1862
  9. Wardman P. Chemical radiosensitizers for use in radiotherapy. Clin Oncol. 2007;19(6):397–417
  10. Latz D, Fleckenstein K, Eble M, Blatter J, Wannenmacher M, Weber KJ. Radiosensitizing potential of gemcitabine (2′,2′-difluoro-2′-deoxycytidine) within the cell cycle in vitro. Int J Radiat Oncol Biol Phys. 1998;41(4):875–882
  11. Lawrence TS, Chang EY, Hahn TM, Hertel LW, Shewach DS. Radiosensitization of pancreatic cancer cells by 2′,2′-difluoro-2′-deoxycytidine. Int J Radiat Oncol Biol Phys. 1996;34(4):867–872
  12. Feng L, Achanta G, Pelicano H, Zhang W, Plunkett W, Huang P. Role of p53 in cellular response to anticancer nucleoside analog-induced DNA damage. Int J Mol Med. 2000;5(6):597–604
  13. Burris HA, Moore MJ, Andersen J, Green MR, Rothenberg ML, Modiano MR, et al. Improvements in survival and clinical benefit with gemcitabine as first-line therapy for patients with advanced pancreas cancer: a randomized trial. J Clin Oncol. 1997;15(6):2403–2413
  14. Orditura M, Martinelli E, Galizia G, Vitiello F, Fasano M, et al. Chemoradiotherapy as adjuvant treatment of gastric cancer. Ann Oncol. 2007;18(Suppl 6):vi133–vi135
  15. Fields MT, Eisbruch A, Normolle D, Orfali A, et al. Radiosensitization produced in vivo by once- vs. twice-weekly 2′2′-difluoro-2′-deoxycytidine (gemcitabine).. Int J Radiat Oncol Biol Phys. 2000;47(3):785–791
  16. Shewach DS, Hahn TM, Chang E, Hertel LW, Lawrence TS. Metabolism of 2′,2′-difluoro-2ô-deoxycytidine and radiation sensitization of human colon carcinoma cells. Cancer Res. 1994;54(12):3218–3223
  17. Shewach DS, Lawrence TS. Gemcitabine and radiosensitization in human tumor cells. Invest New Drugs. 1996;14(3):257–263
  18. Forrer F, Uusijarvi H, Storch D, Maecke HR, Mueller-Brand J. Treatment with 177Lu-DOTATOC of patients with relapse of neuroendocrine tumors after treatment with 90Y-DOTATOC. J Nucl Med. 2005;46(8):1310–1316
  19. Lewington VJ. Targeted radionuclide therapy for neuroendocrine tumours. Endocr Relat Cancer. 2003;10(4):497–501
  20. Lambert B, Cybulla M, Weiner SM, Van De Wiele C, Ham H, Dierckx RA, et al. Renal toxicity after radionuclide therapy. Radic Res. 2004;161(5):607–611
  21. Blackstock AW, Cox AD, Tepper JE. Treatment of pancreatic cancer: current limitations, future possibilities. Oncology (Williston Park, N.Y.). 1996;10(3):301–307[discussion: 308-23]
  22. Crane CH, Varadhachary G, Pisters PW, Evans DB, Wolff RA. Future chemoradiation strategies in pancreatic cancer. Semin Oncol. 2007;34:335–346
  23. Blackstock AW, Govindan R. Definitive chemoradiation for the treatment of locally advanced non small-cell lung cancer. J Clin Oncol. 2007;25(26):4146–4152
  24. Tam KF, Ng TY, Liu SS, Tsang PC, Kwong PW, Ngan HY. Potential application of the ATP cell viability assay in the measurement of intrinsic radiosensitivity in cervical cancer. Gynecol Oncol. 2005;96:765–770
  25. Melis M, Forrer F, Capello A, Bijster M, Bernard BF, Reubi JC, et al. Up-regulation of somatostatin receptor density on rat CA20948 tumors escaped from low dose [(177)Lu-DOTA(0),Tyr(3)]octreotate therapy. Q J Nucl Med Mol Imaging. 2007;51(4):324–333
  26. Capello A, Krenning E, Bernard B, Reubi JC, Breeman W, de Jong M. 111In-labelled somatostatin analogues in a rat tumour model: somatostatin receptor status and effects of peptide receptor radionuclide therapy. Eur J Nucl Med Mol Imaging. 2005;32(11):1288–1295
  27. Oddstig J, Bernhardt P, Nilsson O, Ahlman H, Forssell-Aronsson E. Radiation-induced up-regulation of somatostatin receptor expression in small cell lung cancer in vitro. Nucl Med Biol. 2006;33(7):841–846

PII: S0969-8051(08)00110-8

doi: 10.1016/j.nucmedbio.2008.05.003

Nuclear Medicine and Biology
Volume 35, Issue 6 , Pages 673-678 , August 2008

Article Tools

* Image Usage & Resolution